{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T07:08:42Z","timestamp":1763968122506},"reference-count":38,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The prognosis of adult acute lymphoblastic leukemia (ALL) remains poor and novel treatment strategies are needed. Antibody-based therapies represent such an approach. ALL cells express various surface antigens that are targets for monoclonal antibodies. This review focuses on 4 major classes of antibody therapy: (1) naked antibodies, (2) T-cell-engaging bispecific single-chain antibodies, (3) immunoconjugates\/immunotoxins, and (4) chimeric antigen receptors. Preclinical and clinical data are reviewed. This area of research represents an exciting new approach to help improve the outcome of this disease. Several clinical trials are currently incorporating this therapy in the treatment of newly diagnosed and relapsed adult ALL patients.<\/jats:p>","DOI":"10.1182\/asheducation-2013.1.131","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T15:51:13Z","timestamp":1386345073000},"page":"131-137","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["New immune strategies for the treatment of acute lymphoblastic leukemia: antibodies and chimeric antigen receptors"],"prefix":"10.1182","volume":"2013","author":[{"given":"Anjali S.","family":"Advani","sequence":"first","affiliation":[{"name":"Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, and"},{"name":"Cleveland Clinic Lerner College of Medicine, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"5","key":"2019111703251416200_B1","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1365-2141.2010.08387.x","article-title":"Southwest Oncology Group Study S0530:a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia","volume":"151","author":"Advani","year":"2010","journal-title":"Br J Haematol"},{"issue":"21","key":"2019111703251416200_B2","first-page":"2594","article-title":"Response to high dose cytarabine (HIDAC) as first salvage for relapsed acute lymphocytic leukemia in patients receiving HIDAC as initial therapy [abstract]","volume":"118","author":"Advani","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"31","key":"2019111703251416200_B3","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1200\/JCO.2012.41.6768","article-title":"Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111703251416200_B4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calechiamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol"},{"key":"2019111703251416200_B5","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.hoc.2011.09.019","article-title":"Novel therapeutic approaches for acute lymphoblastic leukemia","volume":"25","author":"Litzow","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"2019111703251416200_B6","first-page":"170","article-title":"Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high-risk patients: results of 263 CD20+ patients studied prospectively in GMALL study 07\/2003 [abstract]","volume":"116","author":"Hoelzer","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"24","key":"2019111703251416200_B7","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111703251416200_B8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30156","article-title":"Rituximab: mechanism of action and resistance","volume":"29","author":"Maloney","year":"2002","journal-title":"Semin Oncol"},{"key":"2019111703251416200_B9","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-07-1254","article-title":"Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulation regulated at the pretranscriptional and posttranscriptional levels","volume":"14","author":"Czuczman","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2019111703251416200_B10","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-06-2184","article-title":"Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy","volume":"67","author":"Jazirehi","year":"2007","journal-title":"Cancer Res"},{"key":"2019111703251416200_B11","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1182\/blood-2008-04-151860","article-title":"Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia","volume":"113","author":"Thomas","year":"2009","journal-title":"Blood"},{"key":"2019111703251416200_B12","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3324\/haematol.2009.010306","article-title":"Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia","volume":"95","author":"Maury","year":"2010","journal-title":"Haematologica"},{"key":"2019111703251416200_B13","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood-2008-06-164129","article-title":"CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment:setting the stage for anti-CD20 directed immunotherapy","volume":"112","author":"Dworzak","year":"2008","journal-title":"Blood"},{"key":"2019111703251416200_B14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1600-065X.2009.00801.x","article-title":"CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions","volume":"230","author":"Nitschke","year":"2009","journal-title":"Immunol Rev"},{"issue":"6","key":"2019111703251416200_B15","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-09-2980","article-title":"Anti-CD22 immunotoxin RB4 (dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood:preclinical studies and phase 1 clinical trial","volume":"16","author":"Wayne","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2019111703251416200_B16","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.molimm.2006.05.007","article-title":"Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab","volume":"44","author":"Carnahan","year":"2007","journal-title":"Mol Immunol"},{"key":"2019111703251416200_B17","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1182\/blood-2011-02-336990","article-title":"Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma","volume":"118","author":"Micallef","year":"2011","journal-title":"Blood"},{"key":"2019111703251416200_B18","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1200\/JCO.2007.15.3528","article-title":"Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse:a Children's Oncology Group pilot study","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019111703251416200_B19","unstructured":"Raetz EA Carroll WL Relapsed ALL: does end-induction MRD predict 1 yr or 2 yr EFS? Intensive induction therapy for children with acute lymphoblastic leukemia who experience a bone marrow relapse: results from COG study AALL01P2. MRD as a Surrogate Endpoint Workshop 2012 4 18 Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/NewsEvents\/UCM300735.pdf"},{"issue":"21","key":"2019111703251416200_B20","first-page":"2603","article-title":"Southwest Oncology Group study S0910:a phase 2 trial of clofarabine\/cytarabine\/epratuzumab for relapsed\/refractory acute lymphocytic leukemia [abstract]","volume":"120","author":"Advani","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"12","key":"2019111703251416200_B21","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/cncr.21901","article-title":"Activity of alemtuzumab in patients with CD52-positive acute leukemia","volume":"106","author":"Tibes","year":"2006","journal-title":"Cancer"},{"issue":"22","key":"2019111703251416200_B22","first-page":"838","article-title":"Alemtuzumab can be incorporated into front-line therapy of adult acute lymphoblastic leukemia (ALL): final phase I results of a Cancer and Leukemia Group B study (CALGB 10102) [abstract]","volume":"114","author":"Stock","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"1","key":"2019111703251416200_B23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncr.27617","article-title":"Dose intensification of daunorubicin and cytarabine during treatment of acute lymphoblastic leukemia: results of Cancer and Leukemia Group B study CALGB 19802","volume":"119","author":"Stock","year":"2013","journal-title":"Cancer"},{"key":"2019111703251416200_B24","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL","volume":"120","author":"Topp","year":"2012","journal-title":"Blood"},{"key":"2019111703251416200_B25","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111703251416200_B26","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"key":"2019111703251416200_B27","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.6500","article-title":"Effect of anti-CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed\/refractory B-precursor ALL","volume":"30","author":"Topp","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111703251416200_B28","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08251.x","article-title":"Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against pediatric acute lymphoblastic leukaemia","volume":"150","author":"Mussai","year":"2010","journal-title":"Br J Haematol"},{"issue":"20","key":"2019111703251416200_B29","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-11-0487","article-title":"Antibody fusion proteins:anti-CD22 recombinant immunotoxin moxetumomab pseudotox","volume":"17","author":"Kreitman","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"18","key":"2019111703251416200_B30","doi-asserted-by":"crossref","first-page":"6898","DOI":"10.1073\/pnas.1204523109","article-title":"Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy","volume":"109","author":"Wei","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111703251416200_B31","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2141.2011.08762.x","article-title":"A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia","volume":"154","author":"Schindler","year":"2011","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111703251416200_B32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4161\/mabs.4.1.18348","article-title":"Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity","volume":"4","author":"Liu","year":"2012","journal-title":"MAbs"},{"key":"2019111703251416200_B33","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1158\/1078-0432.CCR-11-0485","article-title":"SAR3419:an anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies","volume":"17","author":"Blanc","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2019111703251416200_B34","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1078-0432.CCR-12-3613","article-title":"The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse post induction therapy in preclinical models of pediatric acute lymphoblastic leukemia","volume":"19","author":"Carol","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2019111703251416200_B35","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","article-title":"Safety, pharmacokinetics, and preliminary activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma:results of a phase 1 study","volume":"28","author":"Advani","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111703251416200_B36","first-page":"671","article-title":"Experience with 2 dose schedules of inotuzumab ozogamicin, single dose, and weekly, in refractory-relapsed acute lymphocytic leukemia (ALL) [abstract]","volume":"120","author":"Obrien","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"6","key":"2019111703251416200_B37","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.hoc.2011.09.015","article-title":"Cellular therapies in acute lymphoblastic leukemia","volume":"25","author":"Park","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"2019111703251416200_B38","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric-antigen receptor modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/131\/1250416\/bep00113000131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/131\/1250416\/bep00113000131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T17:05:54Z","timestamp":1597165554000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2013\/1\/131\/20822\/New-immune-strategies-for-the-treatment-of-acute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2013.1.131","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]}}}